bsAb CD3-CD28
-
Cat.code:
bsab-tex-1
- Documents
ABOUT
Bispecific T cell engager for effective T cell activation & expansion
The bispecific antibody (bsAb) CD3-CD28 is designed to activate and expand enriched T cell populations or T cells from peripheral blood mononuclear cells (PBMCs).
Its efficacy in activating and expanding enriched CD4+ T cells in the presence of recombinant human IL-2 has been validated using imaging and flow cytometry (see figures).
Key features
- Cost-effective: 1 ml (100 µg/ml) activates and expands up to 100 Mio. T cells
- Simple: no need for magnetic beads, feeder cells, or specialized media
- Versatility: Compatible with transfection or transduction methods
Applications
- T cell research
- Cancer immunotherapy studies
- Understanding T cell responses to bacterial and viral infections
- Development of CAR-T cells
The bsAb CD3-CD28 is a fusion protein dimer comprising tandem single-chain variable fragments (scFv)2 from two monoclonal antibodies (mAbs). These mAbs were derived from the clones OKT3 and 15E8 targeting the human CD3 and CD28 receptors on the cell surface of human T cells, respectively. It mimics the natural cross-linking of these molecules by APCs in vivo and delivers the necessary signal 1 and signal 2 to the T cells for their activation and expansion. This so-called (scFv)2-(scFv)2-Fc molecule belongs to the family of IgG-like antibodies. It features an IgG1 Fc fragment, which contributes to increased solubility, serum half-life, as well as facilitated purification.
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
Phosphate buffer solution (pH 7.4), 5% saccharose
Negative (tested using EndotoxDetect™ assay)
Activation and expansion of T cells confirmed using cellular assays
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:bsAb CD3-CD28
-
Cat code:bsab-tex-1
-
Quantity:100 µg
bsAb CD3-CD28 is provided azide-free and lyophilized
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
T cell activation
Critical to almost all functions of the adaptive immune response is the activation of T cells, such as CD8+ cytotoxic T cells and CD4+ helper T cells. The activation of T cells requires two signals:
- Signal 1: TCR (CD3) engagement with the MHC:peptide complexes on antigen-presenting cells (APCs) [1] and
- Signal 2: A co-stimulatory signal delivered notably by the interaction between the T cell CD28 receptor and CD80 (B7.1) or CD86 (B7.2) on APCs [2].
Importantly, both signals are required for T cell proliferation, cytokine production (e.g. IL-2, IFN-γ), and cellular functions.
T cell-based immunotherapy is an effective strategy to treat a wide range of cancers. Such therapies rely on the ex-vivo activation and expansion of naturally occurring tumor-specific T cells that are otherwise only retrieved in small numbers from the patient's blood or tissues. Importantly, the inherent T cell immune‑modulating functions need to be preserved. A promising approach for the activation of T cells is the use of bispecific antibodies. These unique molecules bring together the specificities of two antibodies and can bind simultaneously to two separate and unique antigens or epitopes such as CD3 and CD28.
References:
1. Brameshuber, M. et al. 2018. Monomeric TCRs drive T cell antigen recognition. Nat Immunol 19, 487-496.
2. Esensten, J.H. et al. 2016. CD28 Costimulation: From Mechanism to Therapy. Immunity 44, 973-988.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
Powered by Bioz
